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Purpose. To define the biology driving the aggressive nature of breast cancer arising in young women. Experimental Design.
Among 784 patients with early stage breast cancer, using prospectively-defined, age-specific cohorts (young #45 years; older
$65 years), 411 eligible patients (n = 200#45 years; n = 211$65 years) with clinically-annotated Affymetrix microarray data
were identified. GSEA, signatures of oncogenic pathway deregulation and predictors of chemotherapy sensitivity were
evaluated within the two age-defined cohorts. Results. In comparing deregulation of oncogenic pathways between age
groups, a higher probability of PI3K (p = 0.006) and Myc (p = 0.03) pathway deregulation was observed in breast tumors arising
in younger women. When evaluating unique patterns of pathway deregulation, a low probability of Src and E2F deregulation
in tumors of younger women, concurrent with a higher probability of PI3K, Myc, and b-catenin, conferred a worse prognosis
(HR= 4.15). In contrast, a higher probability of Src and E2F pathway activation in tumors of older women, with concurrent low
probability of PI3K, Myc and b-catenin deregulation, was associated with poorer outcome (HR=2.7). In multivariate analyses,
genomic clusters of pathway deregulation illustrate prognostic value. Conclusion. Results demonstrate that breast cancer
arising in young women represents a distinct biologic entity characterized by unique patterns of deregulated signaling
pathways that are prognostic, independent of currently available clinico-pathologic variables. These results should enable
refinement of targeted treatment strategies in this clinically challenging situation.
Citation: Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, et al (2008) Age-Specific Differences in Oncogenic Pathway Deregulation Seen in
Human Breast Tumors. PLoS ONE 3(1): e1373. doi:10.1371/journal.pone.0001373
INTRODUCTION
Young women diagnosed with breast cancer have a poorer overall
survival and are twice as likely to recur when compared with older
counterparts [1–3]. Many investigations have addressed the basis
for the aggressive nature of breast cancer arising in young women.
Multiple hypotheses exist, including the lower prevalence of
hormone receptor positivity, higher grade tumors, larger tumors,
and a higher incidence of Her2 overexpression, lymphovascular
invasion, and lymph node positive disease among young women
[2,4,5]. Despite a higher incidence of negative prognostic factors,
young age as a single variable has consistently proven to be an
independent predictor of adverse outcome [6–8]. At the present
time, the underlying biology driving the aggressive nature of breast
cancer arising in young women has yet to be defined.
We recently reported that gene-expression signatures can be
identified to reflect the status of several important oncogenic
pathways (i.e. Ras, Myc, E2F, b-catenin, and Src) that are central
to both cell growth and fate [9]. We have evaluated the clinical
significance of patterns of oncogenic pathway deregulation in over
700 patients with primary breast tumors to illustrate the unique
biologic phenotype of breast cancer arising in young women.
MATERIALS AND METHODS
Dataset and Patient Selection
Four, publicly-available datasets were employed to perform our
analysis: Bild et al. (GSE3143) [9], Wang et al. (GSE2034) [10],
Ivshina et al. (GSE4922) [11], and a large cohort of samples from
the Duke tumor bank (GEO accession user name: ander118,
password: IGSP). The selected datasets, based on either the
Affymetrix Human Genome U133A or U95 array, provided
clinically-annotated gene expression probabilities from early stage
breast tumors. For details specific to each dataset, see Supple-
mentary Table S1 [12]. Prior to applying signatures of pathway
deregulation, all data was RMA-normalized. Further, for U95
data, a previously described annotation and cross reference tool
(Chipcomparer) that facilitates for comparison across Affymetrix
platforms (U95 and U133) by matching corresponding probeids
and relative expression values was employed. The complete details
are described in the Supplementary Methods S1 [9,13]. In total,
784 clinically-annotated breast tumor samples were available for
analysis. All samples were analyzed and reported according to
MIAME guidelines.
Initially, we prospectively, pre-defined tumors arising in young
versus older women by performing a receiver operator character-
istics (ROC) curve based on estrogen receptor (ER) status and
patient age at the time of breast cancer diagnosis based on the
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historical observation that breast tumors arising in younger women
characteristically exhibit quantitatively less ER expression when
compared to older women (Supplementary Figure S1) [4]. Based
on the results of the ROC curve, young age was defined as
#45 years (p,0.001) and data from 200 women met this age cut-
off. Tumors arising in women$65 years (n = 211) were selected to
represent an older, post-menopausal comparison group. The
remaining 373 patients were between the ages of 45 and 65 years
and were not included in this analysis as our goal was to compare
breast tumors arising at the extremes of age.
Oncogenic Pathway and Chemotherapy Sensitivity
Analyses
Previously described signatures of oncogenic pathway deregulation
and chemotherapy sensitivity were applied to clinically-annotated
microarray data using MatLab Software, Version7.0.4 as detailed
in Supplementary Methods S1 [9,13–16].
In brief, oncogenic pathway signatures were developed using
human primary mammary epithelial cell cultures and recombinant
adenoviruses expressing various oncogenic activities in an otherwise
quiescent cell. RNA from multiple independent transfections was
collected for DNA microarray analysis using the Affymetrix Human
Genome U133 Plus 2.0 Array. Gene expression signatures reflecting
the activity of a given oncogenic pathway were identified defining a
relevant phenotype-related metagene. Regression models then
assigned the relative probability of pathway deregulation in tumor
or cell line samples [9]. A correlation was observed between the
likelihood of pathway deregulation and biochemical and molecular
correlates, including mutational analyses of the individual genes
involved in the pathway (i.e. Ras) [9].
Gene expression signatures predicting sensitivity to individual
chemotherapeutic drugs were developed using the NCI-60 panel
from the National Cancer Institute (NCI) as described previously
[13]. Briefly, genes correlating most highly with drug sensitivity
were identified and a Bayesian binary regression analysis
differentiated a pattern of drug sensitivity from that of resistance.
A gene expression signature was then identified classifying cell
lines and tumors on the basis of chemotherapy sensitivity.
Specific to this analysis, heatmaps generated via hierarchical
clustering were generated using ‘‘R’’ software (http://www.r-
project.org/). Complete linkage clustering was performed using an
open source development software project, bioconductor, ver 1.9,
for the analysis of microarray expression data with the uncentered
correlation similarity metric.
Standard Kaplan-Meier survival curves were generated for
clusters of patients with similar patterns of oncogenic pathway
deregulation using GraphPad Prism Software, version 4.03.
Differences in survival were tested for statistical significance using
a two-sided log-rank test using GraphPad Prism Software, version
4.03. This test generates a two-tailed P value testing the null
hypothesis, which is that the survival curves are identical in the
overall populations. Therefore, the null hypothesis is that the
populations have no differences in disease-free survival.
Individual differences in the probability of oncogenic pathway
deregulation between women aged #45 years and $65 years
were analyzed via the non-parametric Mann-Whitney U test using
Graph Pad Prism Software, version 4.03. A two-sided p-value less
than 0.05 was considered statistically significant. Results were
validated via Gene Set Enrichment Analysis (GSEA) methodology
(http://www.broad.mit.edu/gsea/). GSEA is a computational
method that determines whether an a priori defined set of genes
shows statistically significant, concordant differences between two
biological states [17].
Finally, chemotherapy sensitivity patterns were assessed across
groups of patients defined by both pathway clusters and age
(#45 years and $65 years). Linear regression analyses were
performed to ascertain correlations where indicated, using Graph
Pad Prism Software, version 4.03.
Multivariate Analyses
Our goal was to determine if cluster (of oncogenic pathway
deregulation) designation was independently significant when
controlling for known clinico-pathologic variables in the prediction
of disease-free survival in early stage breast cancer. A disease-free
survival event was defined as the time from diagnosis to recurrence
or death, whichever occurred first, and was censored at time of last
follow-up for those who were alive. Multivariate Cox Proportional
Hazards regression modeling was used to predict disease-free
survival when considering each age cohort separately. The clinico-
pathologic variables considered included: age at breast cancer
diagnosis, ER and progesterone receptor (PR) status by immuno-
histochemistry or enzyme immunoassay (IHC or EIA, positive vs.
negative), Her2 by IHC (0, 1+, 2+ vs. 3+), tumor grade (1, 2 vs. 3),
tumor size (#2 cm vs. .2 cm), and lymph node status (positive vs.
negative). The dataset with clinico-pathologic variables was
excellent for imputing missing values due to high correlations
among the variables. For multivariate modeling SAS proc MI was
used to impute missing clinico-pathologic data for variables with
less than 50% missing values. For this reason, PR and Her2 were
excluded from all multivariate models. Multivariate models used
the backward selection technique and an alpha of 0.50 [18].
RESULTS
Clinical Characteristics
Clinico-pathologic and demographic data including age at diagnosis,
ER status, lymph node status, and tumor size, with corresponding
gene expression data were available for patients in all four datasets.
PR and Her2 status were available only in the Duke and CODEX
datasets, respectively. A detailed description of the clinico-pathologic
and demographic information for all patients included in the study is
shown in Supplementary Table S2 [12].
Signatures of Oncogenic Pathway Deregulation in
Young Women
The power of gene expression profiling is the ability to understand
biology beyond what may be apparent from the study of clinical
variables or individual gene markers. Nevertheless, the interpre-
tation of large-scale expression data can be a significant challenge.
We have described an alternative approach that makes use of
expression signatures of oncogenic signaling pathways that can be
used to profile the status of oncogenic pathways in a collection of
biological samples, including human tumors.
Using the previously described signatures of oncogenic pathway
deregulation, patterns of pathway deregulation in 200 breast tumor
samples arising in young women aged #45 years were evaluated.
Hierarchical clustering revealed clear patterns of oncogenic pathway
deregulation defining five main clusters (Figure 1A). Analysis of
disease-free survival of patients identified by these clusters revealed
clinically-significant distinctions as a function of the pattern. Patients
in cluster 4 exhibited very good prognosis, patients in three clusters
illustrated intermediate prognosis (clusters 2, 3, and 5) and patients in
cluster 1 illustrated a very poor prognosis (p= 0.14) (Figure 1B). In
further exploration of subgroups, patients defined by cluster 1 had a
poorer disease-free survival when compared to those defined by
cluster 4 (HR 4.15) (Figure 1C).
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In evaluating patterns of pathway deregulation between patients
with extremes in prognosis (Cluster 1 and 4), the most striking
difference is that of Src and E2F. Patients in the poorest prognosis
cluster (cluster 1) are characterized by a low probability of Src and
E2F deregulation in the setting of high probability of PI3K, Myc
and b-catenin deregulation. Conversely, patients in the good
prognosis cluster (cluster 4) are characterized by high probability
of Src and E2F deregulation again in the setting of a high
probability of PI3K, Myc and b-catenin deregulation. The
differential expression of Src and E2F sheds light on the biology
and subsequent behavior of breast cancer arising in young women,
but begs the question if these patterns of pathway deregulation are
governed by other important prognostic variables such as
hormone receptor status.
Breast tumors arising in younger women are known to express
lower levels of ER [4]. To clarify whether or not the pathway
analysis of young women’s tumors is influenced by ER status, we
stratified young women by ER status and re-evaluated oncogenic
pathway deregulation and correlated findings with disease-free
survival. Among young women with ER-positive breast tumors,
two main clusters emerged, again driven by the Src pathway.
Interestingly, the same pattern was seen among ER-negative
breast tumors arising in young women (Supplementary Figure S2A
and S2B, left panels). In analyzing the disease free survival
between clusters, however, the prognosis is similar for both
ER-positive and ER-negative tumors (p = 0.34 and p=0.32,
respectively) (Supplementary Figure S2A and S2B, right panels).
Given the comparable patterns of pathway activation and
corresponding prognosis despite ER classification, we conclude
that the patterns of oncogenic pathway deregulation among breast
tumors arising in young women in this analysis are independent of
ER status. This was further confirmed in a multivariate analysis of
clinico-pathologic variables and genomic clusters of pathway
deregulation. This analysis illustrated that among women aged
#45 years, younger age at diagnosis (HR 2.22, p,0.001) was the
most significant predictor of inferior outcome. Although not
statistically significant, larger tumor size (HR 1.39, p = 0.19) and
positive lymph node status (HR 1.24, p = 0.38) were correlated
with a poorer prognosis. Importantly, genomic pathway cluster
designation remained within the model as an important predictor
of clinical outcome (cluster 1 vs. cluster 4; HR 4.31, p= 0.18)
(Table 1).
Further, we elected to evaluate oncogenic pathway deregulation
among tumors arising in young women as a function of additional
clinico-pathologic variables. Stratification of young women’s
tumors by independent characteristics, including nodal status,
Her2, tumor grade and size, did not reveal a statistically significant
difference in prognosis between clusters defined by pathway
deregulation (Supplementary Figures S3, S4, S5 and S6), further
supporting the conclusion that patterns of oncogenic pathway
deregulation seen in young women are independent of clinico-
pathologic features.
Figure 1. Patterns of pathway deregulation in human breast tumors arising in women aged #45 years. A) Prediction of PI3K, Myc, Ras, b-catenin,
Src and E2F pathway deregulation. Red represents high probability of pathway deregulation, blue represents low probability of pathway
deregulation. Five clusters emerge based on pathway patterns. B) Kaplan Meier survival analysis based on pathway patterns: good prognosis (cluster
4), intermediate prognosis (clusters 2, 3, 5), and poor prognosis (cluster 1), (p = 0.14). C) Kaplan Meier survival analysis comparing clinically-significant
differences between clusters 1 and 4 (HR 4.15).
doi:10.1371/journal.pone.0001373.g001
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Biologic Comparison of Age–specific Cohorts with
Breast Cancer
In parallel with the evaluation of breast tumors arising in young
women, an analysis of breast tumors arising in women aged
$65 years was concurrently performed to provide a comparison
group, allowing the results generated among younger women to be
placed into context. Patterns of pathway deregulation in 211
breast tumor samples arising in women aged $65 years were
evaluated. Six main clusters emerged of which two illustrate
superior prognosis (cluster 3 and cluster 5) and two illustrates an
inferior prognosis (cluster 1 and cluster 6) (p = 0.04) (Figure 2A and
2B). The most distinct difference in disease-free survival was
illustrated between clusters 1 and 3 (HR=2.7, Figure 2C). Poor
prognosis tumors in cluster 1 are characterized by a high probability
of Src and E2F deregulation with concurrent low probability ofMyc,
PI3K, and b-catenin deregulation. Conversely, good prognosis
tumors in cluster 3 are characterized by a high probability of Src and
Ras deregulation in the setting of a low probability ofMyc, PI3K and
b-catenin deregulation. These results suggest that the differential
expression of Ras and E2F may be a driving force underlying the
nature of breast cancer arising in older women.
We also directly compared the probability of pathway
deregulation between tumors arising in patients #45 years and
$65 years of age. Pathways evaluated included E2F, PI3K, Ras,
Myc, b-catenin and Src. There was a higher probability of PI3K
and Myc pathway deregulation observed in tumors arising in
younger women when compared to older women and this
difference was statistically significant (Mann-Whitney U test,
p = 0.006 and p= 0.03, respectively) (Figure 3). The fact that,
when evaluated individually, only two oncogenic pathways were
significantly different between tumors arising in younger versus
older women speaks to the importance of evaluating patterns of
oncogenic pathway deregulation to gain a deeper understanding of
the contributing biologic processes working in concert.
Additionally, as a further validation of our observations, Gene
Set Enrichment Analysis (GSEA) was employed to identify
differences in gene expression profiles from tumors arising in
women aged #45 years (class 1) and $65 years (class 2), thus
Table 1. Multivariate Analysis Among Women Aged
#45 years
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable Hazard Ratio p-value
Age, younger 2.22 ,0.001
Tumor size, .2cm 1.39 0.19
Lymph node, positive 1.24 0.38
Cluster 1 vs 4 4.31 0.18*
*4 degrees of freedom test
doi:10.1371/journal.pone.0001373.t001..
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Figure 2. Patterns of pathway deregulation in human breast tumors arising in women $aged 65 years. A) Prediction of PI3K, Myc, Ras, b-catenin,
Src and E2F pathway deregulation. Red represents high probability of pathway deregulation, blue represents low probability of pathway
deregulation. Six clusters emerge based on pathway patterns. B) Kaplan Meier survival analysis for breast cancer patients aged $65 years based on
pathway patterns: good prognosis (clusters 3,5) and poor prognosis (clusters 1,6), (p = 0.04). C) Kaplan Meier survival analysis for breast cancer
patients comparing clinically-significant differences between clusters 1 and 3 (HR= 2.7).
doi:10.1371/journal.pone.0001373.g002
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validating the above findings [17]. Results confirm that gene sets
involved in both the Myc (p = 0.008) and the AKT pathways
(p = 0.029), a downstream effector of PI3K, were differentially
expressed in tumors arising in younger women in contrast to their
older counterparts [19].
Multivariate modeling evaluating classification of breast tumors
arising in older women by oncogenic pathway clustering and
important clinico-pathologic variables was additionally performed.
Among older women, larger tumor size (HR 2.51, p,0.001) was
the only significant predictor of disease free survival. Additionally,
negative ER status (HR 1.47, p = 0.25), higher grade tumors (HR
1.62, p= 0.13), positive lymph node status (HR 1.66, p = 0.10) and
genomic clusters of pathway deregulation (HR 2.22, p= 0.10)
remained in the model suggesting prognostic values of these
variables. (Table 2). In contrast to the analysis of young women,
age was not a significant predictor of outcome among older
women, again highlighting the profound influence of young age on
breast cancer prognosis.
Chemotherapy Sensitivity Patterns
Finally, genomic-derived signatures of 5-fluorouracil (5-FU),
paclitaxel, docetaxel, adriamycin and cyclophosphamide sensitiv-
ity were applied to identify unique patterns of chemotherapy
sensitivity by age [12]. There was no statistically significant
difference in sensitivity to 5FU, paclitaxel, docetaxel, adriamycin
and cyclophosphamide between women aged #45 years or
$65 years (data not shown). However, as shown in Figure 4A
and 4B, left panels, distinct patterns of chemotherapy sensitivity
exist between age groups.
As a proof-of-principle, we then utilized genomic clusters of
pathway deregulation (as described in Figures 1 and 2) and evaluated
the likelihood of sensitivity by cytotoxic agent. Among women aged
#45 years, there was no statistically significant difference in
predicted chemotherapeutic sensitivities to 5FU, paclitaxel, doc-
etaxel, adriamycin or cyclophosphamide between patients in
genomic cluster 1 (poor prognosis) or genomic cluster 4 (good
prognosis) (Figure 4A, right panel). In contrast, among women aged
$65 years, there was a statistically significant difference in predicted
chemotherapeutic sensitivity to adriamycin between patients in
genomic cluster 1 (poor prognosis, high probability of E2F
deregulation) and genomic cluster 3 (good prognosis, high
probability of Ras deregulation) (p= 0.02, log rank) (Figure 4B,
right panel). Although predicting the likelihood of sensitivity to
individual chemotherapeutic drugs will greatly advance the care of
patients with cancer, our findings are hypothesis-generating and
highlight the importance of developing a prognostic and predictive
strategy to incorporate therapies, as guided by the results of
oncogenic pathway deregulation, into the management of early stage
breast cancer.
DISCUSSION
Breast cancer arising in young women is characterized by a higher
incidence of negative prognostic factors, higher recurrence rates
and poorer overall survival despite aggressive therapies [1–5].
Clearly, the poor survival of this group of patients emphasizes the
importance of identifying molecular characteristics that might be
exploited for new therapeutic strategies. To date, the underlying
biology driving the aggressive nature of this disease entity has yet
to be fully elucidated. More recently, gene expression profiles and
oncogenic pathway signatures have identified distinct breast
Figure 3. Non-parametric T test evaluating pathway probability between tumors arising in younger versus older women. Red represents women
aged #45 years. Blue represents women aged $65 years. The line represents the median.
doi:10.1371/journal.pone.0001373.g003
Table 2. Multivariate Analysis Among Women Aged
$65 years
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable Hazard Ratio p-value
Tumor size, .2cm 2.51 ,0.001
Nuclear Grade, 3 1.62 0.13
ER status, negative 1.47 0.25
Lymph node, positive 1.66 0.10
Cluster 1 vs 3 2.22 0.10*
*5 degrees of freedom test
doi:10.1371/journal.pone.0001373.t002..
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cancer subtypes associated with clinically-relevant disease out-
comes [9,20,21]. In the present study, we have employed a
genomic approach to facilitate the exploration of the biologic
forces driving age-specific differences unique to breast cancer.
Although unique clusters of pathway deregulation are represen-
tative of distinct phenotypes of breast cancer survival, the purpose
of our analysis was not to generate yet another prognostic strategy.
Instead, our goal was to describe an approach that could
potentially explain the age-specific biologic differences seen in
women with breast cancer, while also highlighting the potential for
using targeted agents in a more rational manner–guided by the
knowledge of oncogenic pathway deregulation.
Building on the expertise of applying oncogenic pathway
deregulation, our analysis identified individual subsets of young
women with prognostic differences defined by signatures of signaling
pathway deregulation. Importantly, this analysis has allowed for the
definition of a poorer prognosis subset of young women’s breast
cancer defined by a low probability of Src and E2F deregulation.
Interestingly, this observation is congruent with previous reports
illustrating poorer survival among patients across all ages with breast
tumors characterized by lower than average E2F deregulation [9].
Although mutations in several E2F genes have been detected in
many human cancers, results have been paradoxical [22]. High
levels of E2F have been correlated with poorer outcome in several
solid tumors [23,24]. Conversely, reduced expression has been
associated with aggressive disease suggesting a potential tumor
suppressor role for E2F [25,26]. Furthermore, inactivation of E2F
was found to significantly accelerate tumor development in
transgenic mice expressing Myc. This report parallels our
observations and provides additional insight into specific onco-
genic alterations cooperating with the loss of E2F [27]. It is
postulated that the low probability of E2F pathway deregulation,
in the context of PI3K, Myc and b-catenin pathway deregulation,
is promoting tumorigenesis in this poor prognosis subset of young
women with breast cancer.
Similar to E2F, the Src family kinases have been shown to
contribute to the growth and survival of breast cancer cells [28]. It
has also been observed that breast tumors expressing the
progesterone receptor have higher observed Src activity [29].
Moreover, tumors arising in younger women are less likely to
express either both estrogen and progesterone receptors–an
observation that confers a poorer overall prognosis [3,6]. The
reported positive correlation between Src activity and hormone
receptor status provides a potential explanation for the low
probability of Src pathway, in the context of PI3K, Myc and b-
catenin pathway deregulation, among the poor prognosis subset of
young women in our analysis.
Of perhaps most importance is the potential for this data to
reveal new therapeutic opportunities for patients at highest risk for
breast cancer recurrence. Our past work has demonstrated an
association between predicting pathway deregulation and sensi-
tivity to therapeutics that target a component of the deregulated
Figure 4. Chemosensitivity patterns among women aged #45 years and $65 years with early stage breast cancer. A) LEFT PANEL Hierarchical
clustering of the probability of sensitivity to 5-fluorouracil (5-FU), paclitaxel, docetaxel, adriamycin and cyclophosphamide among 200 breast tumors
arising in women aged #45 years; RIGHT PANEL Linear regression analysis of sensitivity to adriamycin among women in genomic cluster 1 (poor
prognosis) vs. 4 (good prognosis) aged #45 years. B) LEFT PANEL Hierarchical clustering of the probability of sensitivity to 5FU, paclitaxel, docetaxel,
adriamycin and cyclophosphamide among 211 breast tumors arising in women aged$65 years. RIGHT PANEL Linear regression analysis of sensitivity
to adriamycin among women in genomic cluster 1 (poor prognosis) vs. genomic cluster 3 (good prognosis), demonstrating a statistically significant
(p = 0.02, log rank) relationship between clusters (of pathway deregulation) and adriamycin sensitivity.
doi:10.1371/journal.pone.0001373.g004
Young Age and Breast Cancer
PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1373
pathway[9]. The very poor prognosis group of young women with
breast cancer is characterized by deregulation of PI3K, Myc, and
b-catenin pathways. Of these, PI3K-specific therapies are
available and represent a potential strategy that might be applied
for this group of patients. Identification of unique subsets of
patients by prognosis based on oncogenic pathway signatures
provides not only an opportunity to tailor therapeutic approaches
by recurrence risk, but also to incorporate targeted therapies
geared toward individualized tumor biology with the ultimate goal
of improving patient outcome.
SUPPORTING INFORMATION
Figure S1 Receiver operator curve (ROC) curve. ROC curve
evaluating age and ER (IHC or EIA) status based on observations
that breast cancer arising in younger women is less likely to express
ER. Within this dataset, age less than approximately 45 years
confers ER negativity (72% sensitivity; 53% specificity).
Found at: doi:10.1371/journal.pone.0001373.s001 (0.42 MB TIF)
Figure S2 Oncogenic pathway deregulation among human
breast tumors by ER status among women aged #45 years. A)
LEFT PANEL. Hierarchical clustering of ER positive human
breast tumors. Two main clusters emerge: low probability of Src
deregulation (cluster 1) and high probability of Src deregulation
(cluster 2); RIGHT PANEL. Kaplan Meier survival analysis for
patient with ER positive breast cancer based on Src pathway
deregulation. B) LEFT PANEL Hierarchical clustering of ER
negative human breast tumors. Two main clusters emerge: low
probability of Src deregulation (cluster 1) and high probability of
Src deregulation (cluster 2); RIGHT PANEL Kaplan Meier
survival analysis for patients with ER negative breast cancer based
on Src pathway deregulation.
Found at: doi:10.1371/journal.pone.0001373.s002 (0.92 MB TIF)
Figure S3 Pathway deregulation among human breast tumors
arising in women aged #45 years by lymph node status. A) LEFT
PANEL Hierarchical clustering of predictions of pathway
deregulation among lymph node positive human breast tumors;
RIGHT PANEL Kaplan Meier survival analysis for young, lymph
node positive breast cancer patients based on Src pathway
deregulation. B) LEFT PANEL Hierarchical clustering of
predictions of pathway deregulation among lymph node negative
human breast tumors; RIGHT PANEL Kaplan Meier survival
analysis for young, lymph node negative breast cancer patients
based on PI3K pathway deregulation.
Found at: doi:10.1371/journal.pone.0001373.s003 (0.93 MB TIF)
Figure S4 Pathway deregulation among human breast tumors
arising in women aged #45 years by Her2 status. A) LEFT
PANEL Hierarchical clustering of predictions of pathway
deregulation among Her2 0-1+ (IHC) human breast tumors;
RIGHT PANEL Kaplan Meier survival analysis for young, Her2
0-1+ (IHC) breast cancer patients based on PI3K pathway
deregulation. B) LEFT PANEL Hierarchical clustering of
predictions of pathway deregulation among Her2 2-3+ (IHC)
human breast tumors; RIGHT PANEL Kaplan Meier survival
analysis for young, Her2 2-3+ (IHC) breast cancer patients based
on PI3K pathway deregulation.
Found at: doi:10.1371/journal.pone.0001373.s004 (0.65 MB TIF)
Figure S5 Pathway deregulation among human breast tumors
arising in women aged #45 years by grade. A) LEFT PANEL
Hierarchical clustering of predictions of pathway deregulation
among grade 1–2 human breast tumors; RIGHT PANEL Kaplan
Meier survival analysis for young, grade 1–2 breast cancer patients
based on Src pathway deregulation. B ) LEFT PANEL
Hierarchical clustering of predictions of pathway deregulation
among grade 3 human breast tumors; RIGHT PANEL Kaplan
Meier survival analysis for young, grade 3 breast cancer patients
based on PI3K pathway deregulation.
Found at: doi:10.1371/journal.pone.0001373.s005 (0.80 MB TIF)
Figure S6 Pathway deregulation among human breast tumors
arising women aged #45 years by tumor size (T#2 cm vs.
T.2 cm). A) LEFT PANEL. Hierarchical clustering of predic-
tions of pathway deregulation in samples of human breast tumors
#2 cm; RIGHT PANEL Kaplan Meier survival analysis for
young women with breast tumors #2 cm based on Src pathway
deregulation. B) LEFT PANEL. Hierarchical clustering of
predictions of pathway deregulation in samples of human breast
tumors .2 cm; RIGHT PANEL Kaplan Meier survival analysis
for young women with breast tumors .2 cm based on Src
pathway deregulation.
Found at: doi:10.1371/journal.pone.0001373.s006 (0.82 MB TIF)
Table S1 Dataset Details
Found at: doi:10.1371/journal.pone.0001373.s007 (0.02 MB
DOC)
Table S2 Clinical Characteristics by Age (#45 yrs, $65 yrs)
Found at: doi:10.1371/journal.pone.0001373.s008 (0.03 MB
DOC)
Methods S1 Supplementary Methods
Found at: doi:10.1371/journal.pone.0001373.s009 (0.03 MB
DOC)
ACKNOWLEDGMENTS
Portions of this work were previously presented at the 2007 Annual Society
of Clinical Oncology (ASCO) Annual Meeting.
Author Contributions
Conceived and designed the experiments: AP CA KB. Performed the
experiments: AP CA. Analyzed the data: JN JF AP CA CA DH GB KB.
Contributed reagents/materials/analysis tools: SM JN JF YW YZ AP CA
CA DH JM. Wrote the paper: JN AP CA CA DH GB KB. Other: Critical
review: JN KM KG KB. Scientific collaboration: JN KM KG KM.
REFERENCES
1. Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation
between survival and age at diagnosis in breast cancer. N Engl J Med 315:
559–563.
2. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, et al. (2006)
Effects of young age at presentation on survival in breast cancer. BMC Cancer 6:
194.
3. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, et al. (1994)
Relationship of patient age to pathologic features of the tumor and prognosis for
patients with stage I or II breast cancer. J Clin Oncol 12: 888–894.
4. Holli K, Isola J (1997) Effect of age on the survival of breast cancer patients.
Eur J Cancer 33: 425–428.
5. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW (1997) Early-onset
breast cancer–histopathological and prognostic considerations. Br J Cancer 75:
1318–1323.
6. Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors
of outcome: are there age differentials? J Natl Cancer Inst Monogr. pp 35–42.
7. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, et al.
(1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:
1039–1043.
8. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, et al. (2000) Is
chemotherapy alone adequate for young women with oestrogen-receptor-
positive breast cancer? Lancet 355: 1869–1874.
Young Age and Breast Cancer
PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1373
9. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway
signatures in human cancers as a guide to targeted therapies. Nature 439:
353–357.
10. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-
expression profiles to predict distant metastasis of lymph-node-negative primary
breast cancer. Lancet 365: 671–679.
11. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic
reclassification of histologic grade delineates new clinical subtypes of breast
cancer. Cancer Res 66: 10292–10301.
12. Anders C, Hsu D, Broadwater G, Acharya C, Foekens JA, et al. (2007) Young
Age at Diagnosis with Worse Prognosis and Defines a Subset of Breast Cancers
with Shared Patterns of Gene Expression. submitted for publication.
13. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2006) Genomic
signatures to guide the use of chemotherapeutics. Nat Med 12: 1294–1300.
14. Ihaka RaGRE (1996) R: A Language for Data Analysis and Graphics. Journal of
Computational and Graphical Statistics 5: 299–314.
15. Pittman J, Huang E, Nevins J, Wang Q, West M (2004) Bayesian analysis of
binary prediction tree models for retrospectively sampled outcomes. Biostatistics
5: 587–601.
16. West M, Blanchette C, Dressman H, Huang E, Ishida S, et al. (2001) Predicting
the clinical status of human breast cancer by using gene expression profiles. Proc
Natl Acad Sci U S A 98: 11462–11467.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
18. Harrell F (2001) Regression Modeling Strategies: with Applications to Linear
Models Logistic Regression and Survival Analysis. New York: Springer.
19. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. (2004)
PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193–204.
20. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene
expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874.
21. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated
observation of breast tumor subtypes in independent gene expression data sets.
Proc Natl Acad Sci U S A 100: 8418–8423.
22. Johnson DG, Degregori J (2006) Putting the Oncogenic and Tumor Suppressive
Activities of E2F into Context. Curr Mol Med 6: 731–738.
23. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, et al. (2002)
Transcription factor E2F-1 acts as a growth-promoting factor and is associated
with adverse prognosis in non-small cell lung carcinomas. J Pathol 198: 142–156.
24. Han S, Park K, Bae BN, Kim KH, Kim HJ, et al. (2003) E2F1 expression is
related with the poor survival of lymph node-positive breast cancer patients
treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer
Res Treat 82: 11–16.
25. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, et al. (1999) Prognostic
significance of transcription factor E2F-1 in bladder cancer: genotypic and
phenotypic characterization. J Natl Cancer Inst 91: 874–881.
26. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, et al. (2004)
E2F-1 transcription factor immunoexpression is inversely associated with tumor
growth in colon adenocarcinomas. Anticancer Res 24: 3041–3047.
27. Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG (2002) Inactivation of E2f1
enhances tumorigenesis in a Myc transgenic model. Cancer Res 62: 3276–3281.
28. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and
metastasis. Cancer Metastasis Rev 22: 337–358.
29. Lehrer S, O’Shaughnessy J, Song HK, Levine E, Savoretti P, et al. (1989)
Activity of pp60c-src protein kinase in human breast cancer. Mt Sinai J Med 56:
83–85.
Young Age and Breast Cancer
PLoS ONE | www.plosone.org 8 January 2008 | Issue 1 | e1373
